Scientific Program Committee

Monday
February 4 Sessions
Session 5 CROI 2008
i Monday, 8:30-9 am; Auditorium
Session 5–Plenary CME
Morbidity and Mortality in the HAART Era
8
Andrew Phillips
Royal Free and Univ Coll Med Sch, Univ Coll London, UK
Objectives: This session is directed to clinicians and scientists interested in
gaining greater appreciation of the extent of continued morbidity and mortality
occurring during the HAART era, the surprisingly broad spectrum of clinical
disease that might be influenced by HIV infection, and measures that might be
needed to further reduce morbidity and mortality. It is assumed participants in
this session are familiar with basic concepts of HIV progression, such as CD4
count decline and the link between CD4 count level and risk of AIDS, and the
effects of HAART in suppressing viral load and raising the CD4 count, leading
to a reduction in AIDS risk. Participants are further assumed to be broadly
familiar with current guidelines for treating individuals with HIV infection
in developed countries. At the completion of the session, participants should
have greater knowledge of the 3 areas outlined above.
j Monday, 9-9:30 am; Auditorium
Session 6–Plenary CME
Searching the Genome for Determinants
of Response to HIV
9
David Goldstein
Duke Univ, Durham, NC, US
Objectives: This session is directed to clinicians and scientists interested in
how genome-wide association is being applied to study HIV host genetics,
and what has been found with this approach. It is assumed that participants are
familiar with basic genetics, but not with the details of statistical genomics. At
the completion of the session, participants will be knowledgeable about how
genome-wide association studies work, how they are being applied in HIV
genetics, and what new studies are being carried out as part of the CHAVI
program.
4 15th Conference on Retroviruses and Opportunistic Infections
k Monday, 10 -11:45 am; Room 302-304
CME
Session 7–Oral Abstracts
Epidemiology of SIV/HIV Infection and
AIDS-related Malignancies
Moderators:
Marie-Laure Chaix, Hosp Necker, Paris, France
Harold Jaffe, Univ of Oxford, UK
10:00 10 Geographic Distribution of SIV gor in Wild-living
Gorillas from Cameroon
Cecile Neel* 1,2 , F Van Heuverswyn 1 , E Mpoudi Ngole 2 , Y Li 3 ,
B Keele 3 , F Liegeois 1 , C Butel 1 , E Delaporte 1 , B Hahn 3 , and
M Peeters 1
1 UMR145, Inst for Res and Devt, Univ of Montpellier 1, France;
2 PRESICA, Yaounde, Cameroon; and 3 Univ of Alabama at
Birmingham, US
10:15 11 Diagnosis and Monitoring of HIV-1 Group O Infections
in Cameroon
Aurelia Vessiere* 1 , D Rousset 1 , M Leoz 2 , A Depatureaux 2 ,
F Simon 3 , and JC Plantier 2
1 Ctr Pasteur of Cameroon, Yaounde; 2 Hosp Charles Nicolle, Rouen,
France; and 3 Hosp St Louis, Paris, France
10:30 12 New and Old Complex Recombinant HIV-1 Strains
Entering in France among Patients with Primary
Infection in 2004 to 2006: The French ANRS CO06
Primo Cohort Study
P Frange1 , J Galimand1 , M Peeters2 , C Goujard3 , C Deveau4 ,
V Avettand - Fenoel1 , F Souala5 , L Meyer4 , C Rouzioux1 , and
Marie-Laure Chaix* 1
1 2 Ctr Hosp Univ Necker, Paris, France; Inst for Res and Devt,
Montpellier, France; 3Ctr Hosp Univ Bicetre, Le Kremlin-Bicetre,
France; 4INSERM, Le Kremlin Bicetre, France; and 5Ctr Hosp Univ
Pontchaillou, Rennes, France
10:45 13 Recent Phylodynamics of the HIV Epidemic among
MSM in the UK
Gareth Hughes* 1 , A Leigh Brown1 , A Rambaut1 , S Lycett1 , F Lewis2 ,
E Fearnhill3 , and UK Collaborative Group on HIV Drug Resistance
1 2 Univ of Edinburgh, Scotland; Scottish Agricultural Coll, Inverness,
UK; and 3Med Res Council Clinical Trials Unit, London, UK
11:00 14 Changes Over Time in the Risk of Death following
HIV Seroconversion Compared with Mortality in the
General Population
Kholoud Porter* 1 , O Hamouda2 , M Sannes3 , F Boufassa4 ,
A Johnson5 , S Walker1 , and CASCADE Collaboration
1 2 Med Res Council Clinical Trials Unit, London, UK; Robert Koch
Inst, Germany; 3Ulleval Univ Hosp, Oslo, Norway; 4INSERM, Paris,
France; and 5Univ Coll London, UK
11:15 15 Immunodeficiency and Risk of AIDS-defining and Non-
AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort,
1998 to 2006
M Bruyand1,2 , R Thiebaut1,2,3,4 , S Lawson-Ayayi1,2 , P Joly3,4 ,
A Sasco5 , JL Pellegrin2,4 , D Neau2,4 , P Morlat1,2,4 , G Chene1,2,4 ,
Fabrice Bonnet* 1,2,4 , and Groupe d’Epidémiologie Clinique du SIDA
en Aquitaine (GECSA)
1 2 INSERM U593 and CIC-EC7, Bordeaux, France; Ctr Hosp Univ
Bordeaux, France; 3INSERM U875, Bordeaux, France; 4Univ Victor
Segalen, Bordeaux, France; and 5INSERM U897, Bordeaux, France
11:30 16 Insufficient Virus Suppression during HAART Is a
Strong Predictor for the Development of AIDS-related
Lymphoma: German CLINSURV Cohort
Alexander Zoufaly* 1 , HJ Stellbrink2 , M an der Heiden3 ,
C Kollan3 , J van Lunzen1 , O Hamouda3 , and CLINSURV Study Group
1 2 Univ Med Ctr Hamburg-Eppendorf, Germany; IPM Study Ctr,
Hamburg, Germany; and 3Robert Koch Inst, Berlin, Germany